LBI-HTA - Publications - Search - Bortezomib (Velcade®) as consolidation or maintenance therapy after autologous stem-cell transplantation in patients with newly diagnosed multiple myeloma

Hintringer, K. (2012): Bortezomib (Velcade®) as consolidation or maintenance therapy after autologous stem-cell transplantation in patients with newly diagnosed multiple myeloma. DSD: Horizon Scanning in Oncology 29.

[img]PDF - Sie müssen einen PDF-Viewer auf Ihrem PC installiert haben wie z. B. GSview, Xpdf oder Adobe Acrobat Reader
266Kb
Abstract

Up to now, high-dose therapy supported by autologous stem-cell transplantation (ASCT) is considered standard of care for first-line therapy in patients with symptomatic multiple myeloma (MM). The role of bortezomib, a proteasome inhibitor, as consolidation or maintenance therapy after ASCT in patients with newly diagnosed MM is currently investigated in clinical trials. Bortezomib is already approved as monotherapy and in patients with progressive MM or as combination therapy as first-line treatment for transplant-ineligible patients in Europe.
Two recent phase III trials assessed the efficacy and safety of bortezomib within a transplant setting. In both trials, bortezomib was incorporated in the induction regimen prior to ASCT, followed by post-transplant bortezomib as consolidation therapy in one trial and as prolonged maintenance therapy after ASCT in the second trial. Although response rates were better in the bortezomib-containing arm compared to the control arm throughout the course of the studies, its role in the post-transplant setting remains unclear.
Currently there are multiple effective therapeutic options available for the treatment of MM. In order to prolong overall survival and to improve or at least maintain quality of life, the main task will be to determine the most effective sequence and combination of these therapeutic strategies.

Item Type:DSD: Horizon Scanning in Oncology
Keywords:Bortezomib, velcade, multiple myeloma, MM, induction therapy, consolidation therapy, maintenance therapy
Subjects:WB Practice of medicine > WB 300-962 Therapeutics
WH Hemic and lymphatic systems
QV Pharmacology, toxicology, pharmacy > QV 60-370 Pharmacology
Language:English
Series Name:DSD: Horizon Scanning in Oncology 29
Deposited on:12 Sep 2012 12:34
Last Modified:18 Sep 2012 20:08

Repository Staff Only: item control page